Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Placebo
Empagliflozin
Placebo
Placebo
Empagliflozin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Diagnosis of type 2 diabetes mellitus prior to informed consent
Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:
- drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
- pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)
Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)
- for patients without antidiabetic therapy : HbA1c >=7.0 to =<10.0%
- for patients with one oral antidiabetic drug : HbA1c >=7.0 to =<9.5%
Exclusion criteria:
- Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)
- Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)
- Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent
- Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)
Sites / Locations
- 1245.35.002 Boehringer Ingelheim Investigational Site
- 1245.35.001 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Empagliflozin low dose
Empagliflozin high dose
Placebo
Arm Description
Empagliflozin low dose tablet once daily
Empagliflozin high dose tablet once daily
Placebo tablet once daily
Outcomes
Primary Outcome Measures
Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment
The primary endpoint is the change in AUC1-4h for postprandial plasma glucose based on meal tolerance test from baseline after 28 days of treatment. Baseline refers to the last observation prior to administration of randomised study medication.
Secondary Outcome Measures
Full Information
NCT ID
NCT01947855
First Posted
September 18, 2013
Last Updated
December 16, 2014
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT01947855
Brief Title
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Official Title
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic control on no antidiabetic treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Empagliflozin low dose
Arm Type
Experimental
Arm Description
Empagliflozin low dose tablet once daily
Arm Title
Empagliflozin high dose
Arm Type
Experimental
Arm Description
Empagliflozin high dose tablet once daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet matching Empagliflozin low dose
Intervention Type
Drug
Intervention Name(s)
Empagliflozin
Intervention Description
Empagliflozin low dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet matching Empagliflozin high dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet matching Empagliflozin low dose
Intervention Type
Drug
Intervention Name(s)
Empagliflozin
Intervention Description
Empagliflozin high dose tablet once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet matching Empagliflozin high dose
Primary Outcome Measure Information:
Title
Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment
Description
The primary endpoint is the change in AUC1-4h for postprandial plasma glucose based on meal tolerance test from baseline after 28 days of treatment. Baseline refers to the last observation prior to administration of randomised study medication.
Time Frame
1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day -1 (baseline), and 1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Diagnosis of type 2 diabetes mellitus prior to informed consent
Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:
drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)
Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)
for patients without antidiabetic therapy : HbA1c >=7.0 to =<10.0%
for patients with one oral antidiabetic drug : HbA1c >=7.0 to =<9.5%
Exclusion criteria:
Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)
Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)
Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent
Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1245.35.002 Boehringer Ingelheim Investigational Site
City
Shinjyuku-ku, Tokyo
Country
Japan
Facility Name
1245.35.001 Boehringer Ingelheim Investigational Site
City
Suita-shi, Osaka
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
35472672
Citation
Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
Results Reference
derived
PubMed Identifier
31444706
Citation
Nishimura R, Tanaka Y, Koiwai K, Ishida K, Salsali A, Kaspers S, Kohler S, Lund SS. Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Adv Ther. 2019 Oct;36(10):2769-2782. doi: 10.1007/s12325-019-01045-x. Epub 2019 Aug 23.
Results Reference
derived
PubMed Identifier
25633683
Citation
Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015 Jan 30;14:11. doi: 10.1186/s12933-014-0169-9.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info
Learn more about this trial
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs